Floatz logo

Venetoclax

Chronic Eosinophilic Leukemia, Not Otherwise Specified

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Chronic Eosinophilic Leukemia, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Zofran
Fred Hutchinson Cancer Center
Phase 2B
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B

View all 26 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →